A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial To Assess The Efficacy Of Oral Zolmitriptan 2.5mg In The Acute Treatment Of Migraine During The Mild Intensity Phase Of An Attack In Patients Highly Disabled By Migraine (MIDAS Grades III Or IV).
Study identifier:311CIL/0111
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial To Assess The Efficacy Of Oral Zolmitriptan 2.5mg In The Acute Treatment Of Migraine During The Mild Intensity Phase Of An Attack In Patients Highly Disabled By Migraine (MIDAS Grades III Or IV).
Medical condition
migraine
Phase
Phase 3
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Dec 2000
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
